Holen Sie sich die Stockscreener-App
31.29
2.01%
0.5928
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Nasdaq
VKTX August 29th Options Begin Trading - Nasdaq
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies - Seeking Alpha
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results - Insider Monkey
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Yahoo Finance
This Insider Has Just Sold Shares In Viking Therapeutics - simplywall.st
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - MSN
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity - The Motley Fool
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts (NASDAQ:VKTX) - Seeking Alpha
August 22nd Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
Viking Therapeutics, Inc.(NasdaqCM: VKTX) added to Russell Midcap Value Index - MarketScreener
Viking Therapeutics (VKTX): A High-Risk, High-Reward Biotech Play with Institutional Backing - AInvest
Viking Therapeutics (VKTX): Riding Clinical Catalysts in a Post-Danuglipron World - AInvest
Why This Weight Loss Drug Company's Stock Surged Today - AOL.com
Viking Therapeutics stock maintains buy rating as phase 3 trials begin - Investing.com
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 - Yahoo Finance
Viking's New Obesity Drug Enters Final Testing Phase: 14.7% Weight Loss in Earlier Trial Sparks Interest - Stock Titan
Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)? - MSN
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - Yahoo Finance
(VKTX) Proactive Strategies - news.stocktradersdaily.com
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200% - TipRanks
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - MSN
Viking Therapeutics (VKTX) Rises on Expected Developments - MSN
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely - Yahoo Finance
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Investors Are Gobbling Up Shares of These 10 Firms - Insider Monkey
Viking Therapeutics (VKTX) to Participate in B. Riley's Montreal Meeting | VKTX Stock News - GuruFocus
Jim Cramer Nailed These 11 Stock Predictions - Insider Monkey
1 Stock Down 34% This Year to Buy and Hold - AOL.com
Transcript : Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - marketscreener.com
July 25th Options Now Available For Viking Therapeutics (VKTX) - Nasdaq
(VKTX) Investment Analysis - news.stocktradersdaily.com
Viking Therapeutics at Jefferies Conference: Promising Weight Loss Drug - Investing.com
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Could Viking Therapeutics Become the Next Eli Lilly? - The Globe and Mail
3 Best Growth Stocks to Buy in June - The Motley Fool
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? - MSN
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM (NVDA:NASDAQ) - Seeking Alpha
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade) - Seeking Alpha
Viking Therapeutics to Participate at Upcoming Investor Conferen - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences | VKTX Stock News - GuruFocus
Viking Therapeutics to Participate at Upcoming Investor Conferences – Company Announcement - Financial Times
3.33%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):